Bio Essence acquires MediFlow AI software for $3.5M in restricted stock

Bio Essence Corp

Bio Essence (BIOE) entered an Asset Purchase Agreement to buy the MediFlow AI (formerly AcuVital) platform from Zhituo Software.
Purchase price is $3.5 million in restricted common stock, valued at fair market value as determined by BIOE's board.
Closing is expected within 45 days of April 20, 2026, subject to board approval and delivery of assignment documents.
Seller Zhituo Software Co., Limited is a Hong Kong company with no prior relationship to BIOE.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Bio Essence Corp entered into Asset Purchase Agreement with Zhituo Software Co., Limited valued at $3,500,000 (effective 2026-04-20).

Action: entry
Agreement: asset purchase
Counterparty: Zhituo Software Co., Limited
Value: $3,500,000
Effective: 2026-04-20

Exact text from the filing

On April 20, 2026, Bio Essence Corp., a California corporation (“Company”) entered into a Asset Purchase Agreement (“APA”) with Zhituo Software Co., Limited, a company incorporated under the laws of Hong Kong (“Zhituo”).

View on SEC.gov

Browse all material agreements →

Bio Essence Corp filing history →

Source: SEC EDGAR

accession 0001213900-26-047207

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.